You're reading the free version. Trader adds the live tape and alerts.
Start tracking
AVTX Sale Disclosure
Doyle Mittie · SEC Form 4 · Filed Jul 2, 2026
Sale
Calculated transaction value
$93.08K
Doyle Mittie Chief Medical Officer
AVTX
Avalo Therapeutics
AVTX
Transaction date
Jun 30, 2026
Public filing date
Jul 2, 2026
Filing lag
Filed 2 days later
AVTX daily price context
Close on/before transaction
$18.48
Jun 30, 2026
First close after public filing
$19.96
Jul 6, 2026
30-day return after filing
-9.57%
Through Aug 3, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 4,654 shares @ $20
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001918845-26-000022
Filing cohort
Transactions in this filing
Showing 5 of 5
Trades
5
Issuers
1
Estimated value
$143.75K
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Avalo Therapeutics, Inc. AVTX | Exercise | Jun 30, 2026 | $36.37K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Jun 30, 2026 | $14.3K |
| Avalo Therapeutics, Inc. AVTX | Exercise | Jun 30, 2026 | $0 |
| Avalo Therapeutics, Inc. AVTX | Exercise | Jun 30, 2026 | $0 |
| Avalo Therapeutics, Inc. AVTX Current | Sale | Jun 30, 2026 | $93.08K |